Cargando…

Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy

• aPTT correlates poorly with anti-Xa in COVID-19 patients receiving unfractionated heparin. • aPTT potentially underestimates heparin activity compared with anti-Xa in COVID-19 patients receiving unfractionated heparin. • Elevated fibrinogen levels did not correlate with refractory aPTT in COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawlor, Matthew, Gupta, Aakriti, Ranard, Lauren S., Madhavan, Mahesh V., Li, Jianhua, Eisenberger, Andrew, Parikh, Sahil A., Sethi, Sanjum S., Masoumi, Amirali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Letter to the Editors-in-Chief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698679/ https://www.ncbi.nlm.nih.gov/pubmed/33302210 http://dx.doi.org/10.1016/j.thromres.2020.11.030

Ejemplares similares

Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms
por: Whitman-Purves, Emily, et al.
Publicado: (2017)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
por: Rhoades, Ruben, et al.
Publicado: (2021)

Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
por: Monteagudo-Vela, María, et al.
Publicado: (2021)

Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study
por: Saito, Tomoyo, et al.
Publicado: (2023)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
por: Vlot, E.A., et al.
Publicado: (2020)

The missing slope: paradoxical shortening of activated partial thromboplastin time in a patient on unfractionated heparin therapy
por: Lapić, Ivana, et al.
Publicado: (2021)

Clinical Scenarios for Discordant Anti-Xa
por: Vera-Aguilera, Jesus, et al.
Publicado: (2016)

Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay
por: Billoir, Paul, et al.
Publicado: (2022)

Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients
por: Preti, Paola S., et al.
Publicado: (2021)

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19()
por: Huang, Ching-Tai, et al.
Publicado: (2020)

A Recurrent Neural Network Model for Predicting Activated Partial Thromboplastin Time After Treatment With Heparin: Retrospective Study
por: Boie, Sebastian Daniel, et al.
Publicado: (2022)

The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time
por: Samara, Evangelia, et al.
Publicado: (2021)

Iatrogenic Arteriovenous Fistula Following Femoral Access Precipitating High-Output Heart Failure
por: Zilinyi, Robert S., et al.
Publicado: (2021)

Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group
por: Ray, Joel G., et al.
Publicado: (2021)

Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial
por: Aubron, Cécile, et al.
Publicado: (2023)

Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis
por: Moll, Matthew, et al.
Publicado: (2021)

Coronary and cerebral thrombosis in a young patient after mild COVID-19 illness: a case report
por: Ranard, Lauren S, et al.
Publicado: (2020)

International normalized ratio and activated partial thromboplastin time testing
por: Chornenki, Nicholas L. J., et al.
Publicado: (2022)

Dual alternate access sites for the treatment of an ostial left common iliac artery chronic total occlusion
por: Satish, Mohan, et al.
Publicado: (2020)

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era
por: Qin, Wei, et al.
Publicado: (2021)

Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study
Publicado: (2021)

Heparin: Masking of overt disseminated intravascular coagulation, activated partial thromboplastin time prolonged and rebound effect in the form of coagulation disorders: case report
Publicado: (2020)

Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care
por: Thomas, W., et al.
Publicado: (2020)

Comparative analysis on characteristics of two activated partial thromboplastin time reagents
por: Yasui, Yutaro, et al.
Publicado: (2022)

Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!
por: Santoro, Rita Carlotta, et al.
Publicado: (2023)

Right Ventricular Clot in Transit in COVID-19: Implications for the Pulmonary Embolism Response Team
por: Sethi, Sanjum S., et al.
Publicado: (2020)

The Problem of the Lipoid Thromboplastins
por: Milstone, J. H.
Publicado: (1950)

Lipoid Thromboplastin and Trypsin
por: Milstone, J. H., et al.
Publicado: (1954)

Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19
por: Gupta, Aakriti, et al.
Publicado: (2020)

Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19
por: Gupta, Aakriti, et al.
Publicado: (2021)

COVID-19–Specific Strategies for the Treatment of ST-Segment Elevation Myocardial Infarction in China
por: Ranard, Lauren S., et al.
Publicado: (2020)

Activated Partial Thromboplastin Time and Mortality in Coronary Artery Bypass Grafting Patients
por: Zhang, HuanRui, et al.
Publicado: (2022)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Diabetes Mellitus Is Associated with Shortened Activated Partial Thromboplastin Time and Increased Fibrinogen Values
por: Zhao, Ying, et al.
Publicado: (2011)

Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time
por: Spencer, Akpan, et al.
Publicado: (2011)

Coronary Artery Disease Presentation and Its Association with Shortened Activated Partial Thromboplastin Time
por: Sotoudeh Anvari, Maryam, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lk1q6mnskbplggutb8p6f2sqqn